Case 2 was a 29-year-old male with B-ALL and <i>ETV6::RUNX1</i> fusion gene, who developed grade 4 ICANS (seizures, impaired consciousness, epileptic episodes) on day 4 of blinatumomab therapy. This evidence concerns the gene ETV6 and acute lymphoblastic leukemia.